RECRUITING

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Description

This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.

Conditions

Chronic Kidney Disease(CKD)Type 1 Diabetes (T1D)
Talk to us

Related Conditions:

Chronic Kidney Disease(CKD)Type 1 Diabetes (T1D)

Study Overview

On this page

Study Details

Study overview

This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Condition
Chronic Kidney Disease(CKD)
Intervention / Treatment

-

Contacts and Locations

Cleveland

Cleveland Clinic, Cleveland, Ohio, United States, 44195

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. T1D CKD subjects:
  • 1. Adults, males or females diagnosed with T1D
  • 2. Age 18-65 years
  • 3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2)
  • 4. Diagnosed with albuminuria (UACR 30-500 mg/g)
  • 5. On insulin injections or pump
  • 6. On CGM
  • 2. Controls: T1D subjects without CKD
  • 1. Adults, males or females diagnosed with T1D
  • 2. Age 18-65 years
  • 3. No CKD (eGFR \>90 ml/min/1.73 m2)
  • 4. No albuminuria (UACR \<30 mg/g)
  • 5. On insulin injections or pump
  • 6. On CGM
  • 1. Hemoglobin \<9
  • 2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days
  • 3. pregnancy or plans to become pregnant
  • 4. On steroids
  • 5. Diagnosed with cancer, immunosuppression/autoimmune conditions
  • 6. Reported heavy alcohol use or recreational drug use
  • 7. Any condition which jeopardizes patient safety or affects monocytes at physician's discretion

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

The Cleveland Clinic,

Rong M Zhang, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

2026-07-01